NPS Pharmaceuticals is a biopharmaceutical company engaged in bringing orphan products to patients who have rare disorders and few, if any, therapeutic options. The FDA-approved Gattex 0.05 mg/kg/d for subcutaneous injection is the company’s lead product. In addition to its proprietary programs, NPS has a royalty-based portfolio of products and product candidates which includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin and Takeda GmbH. For more information, visit the company’s Web site at www.npsp.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: